Modification of asparagine-linked glycan density for the design of hepatitis B virus virus-like particles with enhanced immunogenicity

Journal of Virology

Volumn 89, Issue 22, 2015, Pages 11312-11322

  Hyakumura, Michiko ^a   Walsh, Renae ^b   Thaysen Andersen, Morten ^c   Kingston, Natalie J ^a   La, Mylinh ^d   Lu, Louis ^d   Lovrecz, George ^d   Packer, Nicolle H ^c   Locarnini, Stephen ^b   Netter, Hans J ^a  

^a MONASH UNIVERSITY   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d CSIRO   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; GLYCAN; HEPATITIS B SURFACE ANTIGEN; N ACETYLGLUCOSAMINE; HEPATITIS B VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; POLYSACCHARIDE; RECOMBINANT VACCINE; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUCOSYLATION; GEL ELECTROPHORESIS; GENE EXPRESSION PROFILING; GLYCOSYLATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPRECIPITATION; INNATE IMMUNITY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION; SIALYLATION; STRUCTURE ACTIVITY RELATION; VIRUS CELL INTERACTION; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; HEK293 CELL LINE; IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ASPARAGINE; CELL LINE; FEMALE; GLYCOSYLATION; HEK293 CELLS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; MICE; MICE, INBRED BALB C; POLYSACCHARIDES; VACCINES, SYNTHETIC; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84945951631     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01123-15     Document Type: Article

References (69)

1. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. 2011. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines 10:1569-1583. http://dx.doi.org/10.1586/erv.11.135.
2. Jennings GT, Bachmann MF. 2009. Immunodrugs: therapeutic VLPbased vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 49:303-326. http://dx.doi.org/10.1146/annurev-pharmtox-061008-103129.
3. Pushko P, Pumpens P, Grens E. 2013. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology 56:141-165. http://dx.doi.org/10.1159/000346773.
4. Jilg W, Schmidt M, Zoulek G, Lorbeer B, Wilske B, Deinhardt F. 1984. Clinical evaluations of a recombinant HBV vaccine. Lancet ii:1174-1175.
5. Zuckerman JN. 2006. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78:169-177. http://dx.doi.org/10.1002/jmv.20524.
6. Busch K, Thimme R. 2015. Natural history of chronic hepatitis B virus infection. Med Microbiol Immunol 204:5-10. http://dx.doi.org/10.1007/s00430-014-0369-7.
7. World Health Organization. 2013. Hepatitis B. Fact sheet no. 204, updated July 2013. World Health Organization, Geneva, Switzerland.
8. Akbar SMF, Furukawa S, Horiike N, Abe M, Hiasa Y, Onji M. 2011. Safety and immunogenicity of hepatitis B surface antigen pulsed dendritic cells in patients with chronic hepatitis B. J Viral Hepat 18:408-414.
9. Bertoletti A, Gehring AJ. 2013. Immune therapeutic strategies in chronic hepatitis B virus infection: virus or inflammation control? PLoS Pathog 9:e1003784. http://dx.doi.org/10.1371/journal.ppat.1003784.
10. Moffat JM, Cheong W-S, Villadangos JA, Mintern JD, Netter HJ. 2013. Hepatitis B virus-like particles access major histocompatibility class I and II antigen presentation pathways in primary dendritic cells. Vaccine 31: 2310-2316. http://dx.doi.org/10.1016/j.vaccine.2013.02.042.
11. Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P. 2013. Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology 57:1303-1313. http://dx.doi.org/10.1002/hep.26132.
12. Cheong W-S, Reiseger J, Turner SJ, Boyd R, Netter HJ. 2009. Chimeric virus-like particles for the delivery of an inserted conserved influenza Aspecific CTL epitope. Antiviral Res 81:113-122. http://dx.doi.org/10.1016/j.antiviral.2008.10.003.
13. Cheong W-S, Drummer HE, Netter HJ. 2009. Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix. J Virol Methods 158:35-40. http://dx.doi.org/10.1016/j.jviromet.2009.01.015.
14. Delpeyroux F, Chenciner N, Lim A, Malpiece Y, Blondel B, Crainic R, van der Werf S, Streeck RE. 1986. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 233:472-475. http://dx.doi.org/10.1126/science.2425433.
15. Michel M, Lone Y-C, Centlivre M, Roux P, Wain-Hobson S, Sala M. 2007. Optimisation of secretion of recombinant HBsAg virus-like particles: impact on the development of HIV-1/HBV bivalent vaccines. Vaccine 25:1901-1911. http://dx.doi.org/10.1016/j.vaccine.2006.08.014.
16. Netter HJ, Macnaughton TB, Woo W-P, Tindle R, Gowans EJ. 2001. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J Virol 75:2130-2141. http://dx.doi.org/10.1128/JVI.75.5.2130-2141.2001.
17. Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R. 2008. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 373:72-84. http://dx.doi.org/10.1016/j.virol.2007.11.005.
18. Vietheer PTK, Boo I, Drummer HE, Netter HJ. 2007. Immunisations with chimeric hepatitis B VLPs to induce potential anti-hepatitis C virus neutralising antibodies. Antivir Ther 12:477-487.
19. Regules JA, Cummings JF, Ockenhouse CF. 2011. The RTS, S vaccine candidate for malaria. Expert Rev Vaccines 10:589-599. http://dx.doi.org/10.1586/erv.11.57.
20. RTS, S Clinical Trials Partnership. 2014. Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11:e1001685. http://dx.doi.org/10.1371/journal.pmed.1001685.
21. Stirk HJ, Thornton JM, Howard CR. 1992. A topological model for hepatitis B surface antigen. Intervirology 33:148-158.
22. Carman WF, Owsianka A, Wallace LA, Dow BC, Mutimer DJ. 1999. Antigenic characterisation of pre-and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. J Hepatol 31:195-201. http://dx.doi.org/10.1016/S0168-8278(99)80213-X.
23. Weinberger KM, Bauer T, Böhm S, Jilg W. 2000. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 81:1165-1174. http://dx.doi.org/10.1099/0022-1317-81-5-1165.
24. Greiner VJ, Egelé C, Oncul S, Ronzon F, Manin C, Klymchenko A, Mély Y. 2010. Characterization of the lipid and protein organization in HBsAg viral particles by steady-state and time-resolved fluorescence spectroscopy. Biochimie 92:994-1002. http://dx.doi.org/10.1016/j.biochi.2010.04.014.
25. Mangold CM, Unckell F, Werr M, Streeck RE. 1997. Analysis of intermolecular disulfide bonds and free sulfhydryl groups in hepatitis B surface antigen particles. Arch Virol 142:2257-2267. http://dx.doi.org/10.1007/s007050050240.
26. Wunderlich G, Bruss V. 1996. Characterization of early hepatitis B virus surface protein oligomers. Arch Virol 141:1191-1205. http://dx.doi.org/10.1007/BF01718824.
27. Mehta A, Lu X, Block TM, Blumberg BS, Dwek RA. 1997. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc Natl Acad Sci U S A 94:1822-1827. http://dx.doi.org/10.1073/pnas.94.5.1822.
28. Gillece-Castro BL, Fisher SJ, Tarentino AL, Peterson DL, Burlingame AL. 1987. Structure and the oligosaccharide portion of human hepatitis B surface antigen. Arch Biochem Biophy 256:194-201. http://dx.doi.org/10.1016/0003-9861(87)90437-1.
29. Hanaoka K, Takasaki S, Kobata A, Miyamoto H, Nakamura T, Mayumi M. 1986. Structure of asparagine-linked sugar chains in the major polypeptide of hepatitis B surface antigen. J Biochem 99:1273-1276.
30. Ito K, Qin Y, Guarnieri M, Garcia T, Kwei K, Mizokami M, Zhang J, Li J, Wands JR, Tong S. 2010. Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol 84:12850-12861. http://dx.doi.org/10.1128/JVI.01499-10.
31. Julithe R, Abou-Jaoudé G, Sureau C. 2014. Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies. J Virol 88:9049-9059. http://dx.doi.org/10.1128/JVI.01161-14.
32. Lu X, Mehta A, Dwek R, Butters T, Block T. 1995. Evidence that N-linked glycosylation is necessary for hepatitis B virus secretion. Virology 213:660-665. http://dx.doi.org/10.1006/viro.1995.0038.
33. Patzer EJ, Nakamura GR, Yaffe A. 1984. Intracellular transport and secretion of hepatitis B surface antigen in mammalian cells. J Virol 51: 346-353.
34. Cheong W-S, Hyakumura M, Yuen L, Warner N, Locarnini S, Netter HJ. 2012. Modulation of the immunogenicity of virus-like particles composed of mutant hepatitis B virus envelope subunits. Antiviral Res 93: 209-218. http://dx.doi.org/10.1016/j.antiviral.2011.11.011.
35. Li P, Haque MA, Blum JS. 2002. Role of disulfide bonds in regulating antigen processing and epitope selection. J Immunol 169:2444-2450. http://dx.doi.org/10.4049/jimmunol.169.5.2444.
36. Mirano-Bascos D, Steede K, Robinson JE, Landry SJ. 2010. Influence of disulfide-stabilized structure on the specificity of helper T-cell and antibody responses to HIV envelope glycoprotein gp120. J Virol 84:3303-3311. http://dx.doi.org/10.1128/JVI.02242-09.
37. Prato S, Fleming J, Schmidt CW, Corradin G, Lopez JA. 2006. Crosspresentation of a human malaria CTL epitope is conformation dependent. Mol Immunol 43:2031-2036. http://dx.doi.org/10.1016/j.molimm.2005.12.014.
38. Al-Barwani F, Young SL, Baird MA, Larsen DS, Ward VK. 2014. Mannosylation of virus-like particles enhances internalization by antigen presenting cells. PLoS One 9:e104523. http://dx.doi.org/10.1371/journal.pone.0104523.
39. Freire T, Zhang X, Dériaud E, Ganneau C, Vichier-Guerre S, Azria E, Launay O, Lo-Man R, Bay S, Leclerc C. 2010. Glycosidic Tn-based vaccines targeting dermal dendritic cells favor germinal center B-cell development and potent antibody response in the absence of adjuvant. Blood 116:3526-3536. http://dx.doi.org/10.1182/blood-2010-04-279133.
40. Sheng KC, Kalkanidis M, Pouniotis DS, Esparon S, Tang CK, Apostolopoulos V, Pietersz GA. 2008. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo. Eur J Immunol 38:424-436. http://dx.doi.org/10.1002/eji.200737578.
41. Doe B, Steimer KS, Walker CM. 1994. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of Nlinked glycans. Eur J Immunol 24:2369-2376. http://dx.doi.org/10.1002/eji.1830241017.
42. Vigerust DJ, Shepherd VL. 2007. Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 15:211-218. http://dx.doi.org/10.1016/j.tim.2007.03.003.
43. Dam TK, Brewer CF. 2010. Lectins as pattern recognition molecules: the effects of epitope density in innate immunity. Glycobiology 20:270-279. http://dx.doi.org/10.1093/glycob/cwp186.
44. Wolfert MA, Boons G-J. 2013. Adaptive immune activation: glycosylation does matter. Nat Chem Biol 9:776-784. http://dx.doi.org/10.1038/nchembio.1403.
45. Gazi U, Martinez-Pomares L. 2009. Influence of the mannose receptor in host immune responses. Immunobiology 214:554-561. http://dx.doi.org/10.1016/j.imbio.2008.11.004.
46. Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar A. 2011. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm Res 28:2288-2301. http://dx.doi.org/10.1007/s11095-011-0459-9.
47. Yao W, Peng Y, Du M, Luo J, Zong L. 2013. Preventative vaccine-loaded mannosylated chitosan nanoparticles intended for nasal mucosal delivery enhance immune responses and potent tumor immunity. Mol Pharm 10:2904-2914. http://dx.doi.org/10.1021/mp4000053.
48. Mishra H, Mishra D, Mishra PK, Nahar M, Dubey V, Jain NK. 2010. Evaluation of solid lipid nanoparticles as carriers for delivery of hepatitis B surface antigen for vaccination using subcutaneous route. J Pharm Pharm Sci 13:495-509.
49. Lim LY, Yuen L, Hammond R, Angus PW, Thompson AJ, Patterson S, Leary T, Yin P, Thomas H, Locarnini S, Walsh R. 2014. Mapping the HBsAg immune phenotype to predict HBsAg loss or decline in chronic hepatitis B in patients receiving nucleot(s)ide analogue therapy, abstr 1623. Hepatology 60(Suppl 1):980A.
50. Jolivet-Reynaud C, Lésenéchal M, O'Donnell B, Becquart L, Foussadier A, Forge F, Battail-Poirot N, Lacaux X, Carman W, Jolivet M. 2001. Localization of hepatitis B surface antigen epitopes present on variants and specifically recognised by anti-hepatitis B surface antigen monoclonal antibodies. J Med Virol 65:241-249. http://dx.doi.org/10.1002/jmv.2026.
51. Paulij WP, de Wit PL, Sünnen CM, van Roosmalen MH, Petersen-van Ettekoven A, Cooreman MP, Heijtink RA. 1999. Localization of a unique hepatitis B virus epitope sheds new light on the structure of hepatitis B virus surface antigen. J Gen Virol 80:2121-2126. http://dx.doi.org/10.1099/0022-1317-80-8-2121.
52. Eren R, Lubin I, Terkieltaub D, Ben-Moshe O, Zauberman A, Uhlmann R, Tzahor T, Moss S, Ilan E, Shouval D, Galun E, Daudi N, Marcus H, Reisner Y, Dagan S. 1998. Human monoclonal antibodies specific to hepatitis B virus generated in a human/mouse radiation chimera: the Trimera system. Immunology 93:154-161.
53. Waters JA, Brown SE, Steward MW, Howard CR, Thomas HC. 1991. Analysis of the antigenic epitopes of hepatitis B surface antigen involved in the induction of a protective antibody response. Virus Res 22:1-12.
54. Chen Y-CJ, Delbrook K, Dealwis C, Mimms L, Mushahwar IK, Mandecki W. 1996. Discontinous epitopes of hepatitis B surface antigen derived from a filamentous phage peptide library. Proc Natl Acad Sci U S A 93:1997-2001. http://dx.doi.org/10.1073/pnas.93.5.1997.
55. Jensen PH, Karlsson NG, Kolarich D, Packer NH. 2012. Structural analysis of N-and O-glycans released from glycoproteins. Nat Protoc 7:1299-1310. http://dx.doi.org/10.1038/nprot.2012.063.
56. Sethi MK, Thaysen-Andersen M, Smith JT, Baker MS, Packer NH, Hancock WS, Fanayan S. 2014. Comparative N-glycan profiling of colorectal cancer cell lines reveals unique bisecting GlcNAc and α-2,3-linked sialic acid determinants are associated with membrane proteins of the more metastatic/aggressive cell lines. J Proteome Res 13:277-288. http://dx.doi.org/10.1021/pr400861m.
57. Venkatakrishnan V, Thaysen-Andersen M, Chen SC, Nevalainen H, Packer NH. 2015. Cystic fibrosis and bacterial colonization define the sputum N-glycosylation phenotype. Glycobiology 25:88-100. http://dx.doi.org/10.1093/glycob/cwu092.
58. Moh ES, Thaysen-Andersen M, Packer NH. 2015. Relative versus absolute quantitation in disease glycomics. Proteomics Clin Appl http://dx.doi.org/10.1002/prca.201400184.
59. Leymarie N, Griffin PJ, Jonscher K, Kolarich D, Orlando R, McComb M, Zaia J, Aguilan J, Alley WR, Altmann F, Ball LE, Basumallick L, Bazemore-Walker CR, Behnken H, Blank MA, Brown KJ, Bunz SC, Cairo CW, Cipollo JF, Daneshfar R, Desaire H, Drake RR, Go EP, Goldman R, Gruber C, Halim A, Hathout Y, Hensbergen PJ, Horn DM, Hurum D, Jabs W, Larson G, Ly M, Mann BF, Marx K, Mechref Y, Meyer B, Möginger U, Neusüß C, Nilsson J, Novotny MV, Nyalwidhe JO, Packer NH, Pompach P, Reiz B, Resemann A, Rohrer JS, Ruthenbeck A, Sanda M, Schulz JM, Schweiger-Hufnagel U, Sihlbom C, Song E, Staples GO, Suckau D, Tang H, Thaysen-Andersen M, Viner RI, An Y, Valmu L, Wada Y, Watson M, Windwarder M, Whittal R, Wuhrer M, Zhu Y, Zou C. 2013. Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics 12:2935-2951. http://dx.doi.org/10.1074/mcp. M113.030643.
60. Dubois MF, Pourcel C, Rousset S, Chany C, Tiollais P. 1980. Excretion of hepatitis B surface antigen particles from mouse cells transformed with cloned viral DNA. Proc Natl Acad Sci U S A 77:4549-4553. http://dx.doi.org/10.1073/pnas.77.8.4549.
61. Moriarty AM, Hoyer BH, Shih JW, Gerin JL, Hamer DH. 1981. Expression of the hepatitis B virus surface antigen gene in cell culture using a simian virus 40 vector. Proc Natl Acad Sci U S A 78:2606-2610. http://dx.doi.org/10.1073/pnas.78.4.2606.
62. Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, Locarnini SA, Bartholomeusz A. 2007. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 75:64-74.
63. Tanaka H, Chiba H, Inokoshi J, Kuno A, Sugai T, Takahashi A, Ito Y, Tsunoda M, Suzuki K, Takenaka A, Sekiguchi T, Umeyama H, Hirabayashi J, Omura S. 2009. Mechanism by which the lectin actinohivin blocks HIV infection of target cells. Proc Natl Acad Sci U S A 106:15633-15638. http://dx.doi.org/10.1073/pnas.0907572106.
64. Denda-Nagai K, Aida S, Saba K, Suzuki K, Moriyama S, Oo-Puthinan S, Tsuiji M, Morikawa A, Kumamoto Y, Sugiura D, Kudo A, Akimoto Y, Kawakami H, Bovin NV, Irimura T. 2010. Distribution and function of macrophage galactose-type C-type lectin 2 (MGL2/CD301b): efficient uptake and presentation of glycosylated antigens by dendritic cells. J Biol Chem 285:19193-19204. http://dx.doi.org/10.1074/jbc. M110.113613.
65. Thaysen-Andersen M, Packer NH. 2014. Advances in LC-MS/MS-based glycoproteomics: getting closer to system-wide site-specific mapping of the N-and O-glycoproteome. Biochim Biophys Acta 1844:1437-1452. http://dx.doi.org/10.1016/j.bbapap.2014.05.002.
66. Lee LY, Lin C-H, Fanayan S, Packer NH, Thaysen-Andersen M. 2014. Differential site accessibility mechanistically explains subcellular-specific N-glycosylation determinants. Front Immunol 5:404.
67. Thaysen-Andersen M, Packer NH. 2012. Site-specific glycoproteomics confirms that protein structure dictates formation of N-glycan type, core fucosylation and branching. Glycobiology 22:1440-1452. http://dx.doi.org/10.1093/glycob/cws110.
68. Yu D-M, Li X-H, Mom V, Lu Z-H, Liao X-W, Han Y, Pichoud C, Gong Q-M, Zhang D-H, Zhang Y, Deny P, Zoulim F, Zhang X-X. 2014. N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. J Hepatol 60:515-522. http://dx.doi.org/10.1016/j.jhep.2013.11.004.
69. Butler M, Spearman M. 2014. The choice of mammalian cell host and possibilities for glycosylation engineering. Curr Opin Biotechnol 30:107-112. http://dx.doi.org/10.1016/j.copbio.2014.06.010.